Recent studies using SIMOA have emphasized the role of plasma t-tau/Aβ42 in the prediction of brain tau pathology and neurodegeneration in AD and have also demonstrated a positive correlation of phospho-tau181 levels with clinical AD severity and deposition of tau and Aβ detected by PET15,38. Here, MAPT is linked to Alzheimer disease.